U.S. Markets close in 5 hrs 27 mins
  • S&P 500

    3,896.98
    -28.45 (-0.72%)
     
  • Dow 30

    31,816.47
    -145.39 (-0.45%)
     
  • Nasdaq

    13,461.66
    -136.31 (-1.00%)
     
  • Russell 2000

    2,272.37
    -12.01 (-0.53%)
     
  • Crude Oil

    62.96
    -0.26 (-0.41%)
     
  • Gold

    1,776.60
    -21.30 (-1.18%)
     
  • Silver

    27.90
    -0.03 (-0.10%)
     
  • EUR/USD

    1.2228
    +0.0060 (+0.4891%)
     
  • 10-Yr Bond

    1.4610
    +0.0720 (+5.18%)
     
  • Vix

    22.85
    +1.51 (+7.08%)
     
  • GBP/USD

    1.4162
    +0.0020 (+0.1444%)
     
  • USD/JPY

    106.1690
    +0.2870 (+0.2711%)
     
  • BTC-USD

    51,021.18
    +1,499.25 (+3.03%)
     
  • CMC Crypto 200

    1,019.98
    +25.31 (+2.54%)
     
  • FTSE 100

    6,679.87
    +20.90 (+0.31%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Rigel to Present at the Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., May 26, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 p.m. Eastern Time.

To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and will be marketed in Europe under the name TAVLESSE® (fostamatinib).

Rigel's clinical programs include a Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (AIHA); a completed Phase 1 study of R8351, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R5521, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

Please see www.TAVALISSE.com for the full Prescribing Information.

1This product candidate is investigational and has not been established safe or effective by the U.S. Food and Drug Administration (FDA) or any regulatory authority.

Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com

Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)
Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-virtual-healthcare-conference-301064907.html

SOURCE Rigel Pharmaceuticals, Inc.